The past week has been a rollercoaster ride for Apple Inc. AAPL. From a significant stock nosedive to urgent logistics operations, the tech giant has been in the spotlight for various reasons. The escalating U.S.-China tensions and the resulting tariffs have created a sense of panic among investors and consumers alike. Here’s a recap of the top stories that shaped Apple’s tumultuous week.
Apple Stock Nosedives Amid U.S.-China Tensions
According to Gene Munster, Managing Partner at Deepwater Asset Management, Apple investors have “slid into panic mode” as the company’s shares have plummeted 23% since April 2. Munster warned that the situation could worsen due to the escalating U.S.-China tensions. “It's going to get ugly with China over the next month, which will intensify the panic,” he wrote.
Apple Airlifts iPhones to Beat Trump’s Tariffs
In late March, Apple reportedly completed an urgent logistics operation, airlifting five planeloads of iPhones and other products from manufacturing centers in India and China to the U.S. within 72 hours. This move was in response to President Donald Trump's new 10% reciprocal tariff on imports that took effect on April 5.
Apple Customers Rush to Stores Amid Tariff Threats
Following the announcement of higher tariffs on Chinese goods, including a 25% levy on electronics, U.S. consumers reportedly rushed to Apple stores to purchase new iPhones ahead of potential price hikes.
Apple Plans More iPhone Production in India
To mitigate the financial impact of escalating tariffs on Chinese goods, Apple is reportedly shifting more of its iPhone production to India. This move could potentially offset the projected 30% to 40% price increase on its device.
Apple Analyst Slashes Price Forecast
Despite the lower tariff risk, Jefferies analyst Edison Lee downgraded Apple’s price target from $202.33 to $167.88 on Wednesday due to weak iPhone demand and AI revenue. However, he upgraded the company from Underperform to Hold.
Read Next:
Photo courtesy: Shutterstock
This story was generated using Benzinga Neuro and edited by Rounak Jain
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.